CGRP阻害剤の世界市場（2023年版）：治療法別（予防、急性期）、投与経路別（経口、経鼻、静脈）、エンドユーザー別、地域別、国別の分析：市場インサイトと予測（2019-2029年）

Global CGRP Inhibitor Market (2023 Edition): Analysis By Treatment (Preventive, Acute), Route of Administration (Oral, Nasal, Intravenous), By End-User, By Region, By Country: Market Insights and Forecast (2019-2029)

エグゼクティブ・サマリー Azoth Analytics社はこのたび、「CGRP阻害剤の世界市場（2023年版）」と題する調査報告書を発表しました。この調査報告書では、CGRP阻害剤の世界市場について、治療法別（予防、急性... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Azoth Analytics アーゾスアナリティクス	2023年9月1日	US$2,450 シングルユーザライセンスライセンス・価格情報注文方法はこちら	230	英語

サマリー

エグゼクティブ・サマリー

Azoth Analytics社はこのたび、「CGRP阻害剤の世界市場（2023年版）」と題する調査報告書を発表しました。この調査報告書では、CGRP阻害剤の世界市場について、治療法別（予防、急性期）、投与経路別（経口、鼻腔、静脈内）、エンドユーザー別（病院、薬局、専門クリニック）、地域別（米州、欧州、アジア太平洋、中近東）の完全な分析を掲載しています、投与経路別（経口、経鼻、静脈）、エンドユーザー別（病院、薬局、専門クリニック）、地域別（米州、欧州、アジア太平洋、中東・アフリカ）、過去期間2019-2022年、予測期間2023年、予測期間2024-2029年について掲載しています。

調査レポートは、地域（米州、欧州、APAC、中東アフリカ）と10カ国（米国、カナダ、英国、ドイツ、フランス、イタリア、スペイン、中国、日本、韓国）の詳細な分析をカバーしている。さらに、市場規模、年間成長率、将来性分析、市場プレイヤーの競合調査、投資機会、需要予測などのデータも掲載しています。

また調査レポートは、成長指標、阻害要因、需給リスク、その他の重要な統計、市場の進化に関連する現在および将来の市場動向の完全な評価も行っています。

CGRP阻害剤の世界市場は、2022年の15億米ドルから2029年末までに56億米ドルを創出すると予測されています。世界のCGRP阻害剤市場にとって好ましい成長要素は、標的治療薬に対する需要の高まり、片頭痛の高い有病率、片頭痛治療という満たされていない医療要件です。2024年から2029年の予測期間中、世界のCGRP阻害剤はCAGR 21％で拡大する見込みです。ハイスループットスクリーニング、ゲノミクス、バイオインフォマティクス技術は、CGRP経路のような潜在的な薬物標的の迅速な同定と検証を可能にした。これらの技術は、片頭痛の病態生理学における重要なプレーヤーとしてのCGRPの発見を早めた。これらの技術は、CGRP阻害剤を開発するための潜在的な治療標的としてのCGRP受容体の同定を容易にした。

CGRP阻害剤は、片頭痛治療のパラダイムシフトを促し、急性症状の緩和が中心であった治療から予防的管理へと移行した。この転換は、患者の幸福を高めるために予防的ケアに焦点を当てるという、より広範なヘルスケアのトレンドと一致している。片頭痛発作を予防する選択肢を提供することで、CGRP阻害剤は患者に自分の状態をより高度にコントロールできるようにし、反応的介入や緊急治療の必要性を減らす。

静脈内投与セグメントは、薬剤が血流に直接送達されるため、静脈内投与ルートで最も早く作用が発現することから、広く受け入れられている。これは重度の急性片頭痛発作に有効である。さらに、患者によっては自分で皮下注射を行うことが困難であったり、医療従事者による投与を希望する場合もある。そのような場合、病院はCGRP阻害薬を静脈注射する役割を果たすことができる。

CGRP阻害剤の開発と商業化は、医薬品イノベーションの最たるものである。片頭痛の病態生理学におけるCGRPの極めて重要な役割の発見と、それに続く標的阻害剤の設計は、患者ケアの進歩に対する業界のコミットメントを浮き彫りにしている。この技術革新は医薬品開発にとどまらず、患者の利便性と服薬アドヒアランスを向上させる新しい薬物送達方法、製剤、投与レジメンにまで及んでいます。

片頭痛の遺伝的・生理学的基盤の理解における進歩は、個別化医療への道を開いた。CGRP阻害剤は、医療従事者が個々の患者のプロファイル、嗜好、反応性に基づいて治療計画を調整できるようにすることで、この傾向を例証している。このような個別化アプローチは、治療結果と患者の満足度を高め、CGRP阻害剤の需要を促進している。

レポートの範囲

- このレポートはCGRP阻害剤市場を金額（百万米ドル）別に分析しています。

- CGRP阻害剤市場の過去期間2019-2022年、推定期間2023年、予測期間2024-2029年の分析を紹介しています。

- CGRP阻害剤市場を治療別（予防、急性期）に分析しています。

- CGRP阻害剤市場を投与経路別（経口、経鼻、静脈内）に分析しています。

- CGRP阻害剤市場をエンドユーザー別（病院、薬局、専門クリニック）に分析しています。

- 本レポートの主要な洞察は、SWOTおよびポーターのファイブフォース分析の枠組みを通して提示されています。また、市場の魅力を地域別、サービス別、運営形態別、エンドユーザー別に紹介しています。

- また、業界の主な機会、動向、促進要因、課題についても分析しています。

- 本レポートでは、競合の動向、戦略、M&A、新製品開発などを追跡しています。本レポートで分析対象とした企業は、イーライリリー・アンド・カンパニー、ファイザー、テバ・ファーマシューティカルズ、ルンドベック、アッヴィ・インク、アムジェン・インク、ノバルティスなどです。

ページTOPに戻る

1. Market Background

1.1 Scope and Product Outlook

1.2 Executive Summary

1.3 Research Methodology

2. Strategic Recommendations

2.1 The development of biosimilar and generic versions of existing CGRP inhibitors

2.2 Use of CGRP inhibitors to new indications beyond migraine treatment

3. Global CGRP Inhibitor Market: Historic and Forecast (2019-2029)

3.1 CGRP Inhibitor studies in the pipeline

3.2 Prevalence of Migraine, 2019 (in Millions)

3.3 Migraine: Fact Sheet

3.4 Global CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

3.5 Degree of Impact of COVID-19 on the CGRP Inhibitor Market

3.6 Global CGRP Inhibitor Market Segmentation: By Treatment

3.6.1 Global CGRP Inhibitor Market, By Treatment Overview

3.6.2 Global CGRP Inhibitor Market Size, By Preventive, By Value, 2019H-2029F (USD Million & CAGR)

3.6.3 Global CGRP Inhibitor Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)

3.7 Global CGRP Inhibitor Market Segmentation: By Route of Administration

3.7.1 Global CGRP Inhibitor Market, By Route of Administration Overview

3.7.2 Global CGRP Inhibitor Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)

3.7.3 Global CGRP Inhibitor Market Size, By Nasal, By Value, 2019H-2029F (USD Million & CAGR)

3.7.4 Global CGRP Inhibitor Market Size, By Intravenous, By Value, 2019H-2029F (USD Million & CAGR)

3.8 Global CGRP Inhibitor Market Segmentation: By End-User

3.8.1 Global CGRP Inhibitor Market, By End-User Overview

3.8.2 Global CGRP Inhibitor Market Size, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)

3.8.3 Global CGRP Inhibitor Market Size, By Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)

3.8.4 Global CGRP Inhibitor Market Size, By Specialty Clinics, By Value, 2019H-2029F (USD Million & CAGR)

4. Global CGRP Inhibitor Market, Regional Analysis

4.1 Regional Coverage of the Study

4.2 Regional Snapshot

5. Americas CGRP Inhibitor Market: Historic and Forecast (2019-2029)

5.1 Americas CGRP Inhibitor Market: Snapshot

5.2 Americas CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

5.3 Americas CGRP Inhibitor Market: Key Factors

5.4 Americas CGRP Inhibitor Market Segmentation: By Treatment

5.4.1 Americas CGRP Inhibitor Market, By Treatment Overview

5.4.2 Americas CGRP Inhibitor Market Size, By Preventive, By Value, 2019H-2029F (USD Million & CAGR)

5.4.3 Americas CGRP Inhibitor Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)

5.4 Americas CGRP Inhibitor Market Segmentation: By Route of Administration

5.4.1 Americas CGRP Inhibitor Market, By Route of Administration Overview

5.4.2 Americas CGRP Inhibitor Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)

5.4.3 Americas CGRP Inhibitor Market Size, By Nasal, By Value, 2019H-2029F (USD Million & CAGR)

5.4.4 Americas CGRP Inhibitor Market Size, By Intravenous, By Value, 2019H-2029F (USD Million & CAGR)

5.5 Americas CGRP Inhibitor Market Segmentation: By End-User

5.5.1 Americas CGRP Inhibitor Market, By End-User Overview

5.5.2 Americas CGRP Inhibitor Market Size, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)

5.5.3 Americas CGRP Inhibitor Market Size, By Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)

5.5.4 Americas CGRP Inhibitor Market Size, By Specialty Clinics, By Value, 2019H-2029F (USD Million & CAGR)

5.6 Americas CGRP Inhibitor Market Segmentation: By Country

5.6.1 Americas CGRP Inhibitor Market, By Country Overview

5.6.2 United States CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

5.6.2.1 United States CGRP Inhibitor Market, By Treatment

5.6.2.2 United States CGRP Inhibitor Market, By Route of Administration

5.6.2.3 United States CGRP Inhibitor Market, By End-User

5.6.3 Canada CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

5.6.3.1 Canada CGRP Inhibitor Market, By Treatment

5.6.2.2 Canada CGRP Inhibitor Market, By Route of Administration

5.6.3.3 Canada CGRP Inhibitor Market, By End-User

5.6.4 Rest of Americas CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

5.6.4.1 Rest of Americas CGRP Inhibitor Market, By Treatment

5.6.4.2 Rest of Americas CGRP Inhibitor Market, By Route of Administration

5.6.4.4 Rest of Americas CGRP Inhibitor Market, By End-User

6. Europe CGRP Inhibitor Market: Historic and Forecast (2019-2029)

6.1 Europe CGRP Inhibitor Market: Snapshot

6.2 Europe CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.3 Europe CGRP Inhibitor Market: Key Factors

6.4 Europe CGRP Inhibitor Market Segmentation: By Treatment

6.4.1 Europe CGRP Inhibitor Market, By Treatment Overview

6.4.2 Europe CGRP Inhibitor Market Size, By Preventive, By Value, 2019H-2029F (USD Million & CAGR)

6.4.3 Europe CGRP Inhibitor Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)

6.5 Europe CGRP Inhibitor Market Segmentation: By Route of Administration

6.5.1 Europe CGRP Inhibitor Market, By Route of Administration Overview

6.5.2 Europe CGRP Inhibitor Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)

6.5.3 Europe CGRP Inhibitor Market Size, By Nasal, By Value, 2019H-2029F (USD Million & CAGR)

6.5.4 Europe CGRP Inhibitor Market Size, By Intravenous, By Value, 2019H-2029F (USD Million & CAGR)

6.6 Europe CGRP Inhibitor Market Segmentation: By End-User

6.6.1 Europe CGRP Inhibitor Market, By End-User Overview

6.6.2 Europe CGRP Inhibitor Market Size, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)

6.6.3 Europe CGRP Inhibitor Market Size, By Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)

6.6.4 Europe CGRP Inhibitor Market Size, By Specialty Clinics, By Value, 2019H-2029F (USD Million & CAGR)

6.7 Europe CGRP Inhibitor Market Segmentation: By Country

6.7.1 Europe CGRP Inhibitor Market, By Country Overview

6.7.2 Germany CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.7.2.1 Germany CGRP Inhibitor Market, By Treatment

6.7.2.2 Germany CGRP Inhibitor Market, By Route of Administration

6.7.2.3 Germany CGRP Inhibitor Market, By End-User

6.7.3 United Kingdom CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.7.3.1 United Kingdom CGRP Inhibitor Market, By Treatment

6.7.3.2 United Kingdom CGRP Inhibitor Market, By Route of Administration

6.7.3.2 United Kingdom CGRP Inhibitor Market, By End-User

6.7.4 France CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.7.4.1 France CGRP Inhibitor Market, By Treatment

6.7.4.2 France CGRP Inhibitor Market, By Route of Administration

6.7.4.3 France CGRP Inhibitor Market, By End-User

6.7.5 Italy CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.7.5.1 Italy CGRP Inhibitor Market, By Treatment

6.7.5.2 Italy CGRP Inhibitor Market, By Route of Administration

6.7.5.3 Italy CGRP Inhibitor Market, By End-User

6.7.6 Spain CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.7.6.1 Spain CGRP Inhibitor Market, By Treatment

6.7.6.2 Spain CGRP Inhibitor Market, By Route of Administration

6.7.6.3 Spain CGRP Inhibitor Market, By End-User

6.7.7 Rest of Europe CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.7.7.1 Rest of Europe CGRP Inhibitor Market, By Treatment

6.7.7.2 Rest of Europe CGRP Inhibitor Market, By Route of Administration

6.7.7.3 Rest of Europe CGRP Inhibitor Market, By End-User

7. Asia Pacific CGRP Inhibitor Market: Historic and Forecast (2019-2029)

7.1 Asia Pacific CGRP Inhibitor Market: Snapshot

7.2 Asia Pacific CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.3 Asia Pacific CGRP Inhibitor Market: Key Factors

7.4 Asia Pacific CGRP Inhibitor Market Segmentation: By Treatment

7.4.1 Asia Pacific CGRP Inhibitor Market, By Treatment Overview

7.4.2 Asia Pacific CGRP Inhibitor Market Size, By Preventive, By Value, 2019H-2029F (USD Million & CAGR)

7.4.3 Asia Pacific CGRP Inhibitor Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)

7.5 Asia Pacific CGRP Inhibitor Market Segmentation: By Route of Administration

7.5.1 Asia Pacific CGRP Inhibitor Market, By Route of Administration Overview

7.5.2 Asia Pacific CGRP Inhibitor Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)

7.5.3 Asia Pacific CGRP Inhibitor Market Size, By Nasal, By Value, 2019H-2029F (USD Million & CAGR)

7.5.4 Asia Pacific CGRP Inhibitor Market Size, By Intravenous, By Value, 2019H-2029F (USD Million & CAGR)

7.6 Asia Pacific CGRP Inhibitor Market Segmentation: By End-User

7.6.1 Asia Pacific CGRP Inhibitor Market, By End-User Overview

7.6.2 Asia Pacific CGRP Inhibitor Market Size, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)

7.6.3 Asia Pacific CGRP Inhibitor Market, By Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)

7.6.4 Asia Pacific CGRP Inhibitor Market, By Specialty Clinics, By Value, 2019H-2029F (USD Million & CAGR)

7.7 Asia Pacific CGRP Inhibitor Market Segmentation: By Country

7.7.1 Asia Pacific CGRP Inhibitor Market, By Country Overview

7.7.2 China CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.7.2.1 China CGRP Inhibitor Market, By Treatment

7.7.2.2 China CGRP Inhibitor Market, By Route of Administration

7.7.2.3 China CGRP Inhibitor Market, By End-User

7.7.3 Japan CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.7.3.1 Japan CGRP Inhibitor Market, By Treatment

7.7.3.2 Japan CGRP Inhibitor Market, By Route of Administration

7.7.3.3 Japan CGRP Inhibitor Market, By End-User

7.7.4 South Korea CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.7.4.1 South Korea CGRP Inhibitor Market, By Treatment

7.7.4.2 South Korea CGRP Inhibitor Market, By Route of Administration

7.7.4.3 South Korea CGRP Inhibitor Market, By End-User

7.7.5 Rest of Asia Pacific CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.7.5.1 Rest of Asia Pacific CGRP Inhibitor Market, By Treatment

7.7.5.2 Rest of Asia Pacific CGRP Inhibitor Market, By Route of Administration

7.7.5.3 Rest of Asia Pacific CGRP Inhibitor Market, By End-User

8. Middle East and Africa CGRP Inhibitor Market: Historic and Forecast (2019-2029)

8.1 Middle East and Africa CGRP Inhibitor Market: Snapshot

8.2 Middle East and Africa CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

8.3 Middle East and Africa CGRP Inhibitor Market: Key Factors

8.4 Middle East and Africa CGRP Inhibitor Market Segmentation: By Treatment

8.4.1 Middle East and Africa CGRP Inhibitor Market, By Treatment Overview

8.4.2 Middle East and Africa CGRP Inhibitor Market Size, By Preventive, By Value, 2019H-2029F (USD Million & CAGR)

8.4.3 Middle East and Africa CGRP Inhibitor Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)

8.5 Middle East and Africa CGRP Inhibitor Market Segmentation: By Route of Administration

8.5.1 Middle East and Africa CGRP Inhibitor Market, By Route of Administration Overview

8.5.2 Middle East and Africa CGRP Inhibitor Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)

8.5.3 Middle East and Africa CGRP Inhibitor Market Size, By Nasal, By Value, 2019H-2029F (USD Million & CAGR)

8.5.4 Middle East and Africa CGRP Inhibitor Market Size, By Intravenous, By Value, 2019H-2029F (USD Million & CAGR)

8.6 Middle East and Africa CGRP Inhibitor Market Segmentation: By End-User

8.6.1 Middle East and Africa CGRP Inhibitor Market, By End-User Overview

8.6.2 Middle East and Africa CGRP Inhibitor Market Size, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)

8.6.3 Middle East and Africa CGRP Inhibitor Market, By Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)

8.6.4 Middle East and Africa CGRP Inhibitor Market, By Specialty Clinics, By Value, 2019H-2029F (USD Million & CAGR)

9. Market Dynamics

9.1 Impact Assessment of Market Dynamics on the Global CGRP Inhibitor Market

9.2 Drivers

9.3 Restraints

9.4 Trends

10. Industry Ecosystem Analysis

10.1 Porter's Five Forces Analysis

11. Competitive Positioning

11.1 Companies’ Product Positioning

11.2 Market Share of Leading Companies

11.3 List of CGRP Inhibitor Drugs

11.4 Company Profiling

11.4.1 Eli Lilly and Company

11.4.2 Pfizer

11.4.3 Teva Pharmaceutical

11.4.4 Lundbeck

11.4.5 AbbVie Inc.

11.4.6 Novartis

11.4.7 Amgen, INC.

ページTOPに戻る

Table of Contents

Summary

Executive Summary

Azoth Analytics has released a research report titled “Global CGRP Inhibitor Market (2023 Edition)” which provides a complete analysis of the Global CGRP Inhibitor industry in terms of market segmentation by Treatment (Preventive, Acute), By Route of Administration (Oral, Nasal, Intravenous), End-User (Hospitals, Pharmacies, Specialty Clinics), By Region (Americas, Europe, Asia-pacific, Middle-East & Africa), for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.

The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, United Kingdom, Germany, France, Italy, Spain, China, Japan, South Korea). Additionally, the research report presents data including market size, yearly growth and potential analysis, the competitive study of market players, investment opportunities and demand forecast.

The research report also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

The Global CGRP Inhibitor Market is expected to generate USD 5.6 billion by the end of 2029, up from USD 1.5 billion in 2022. A favourable growth element for the global CGRP Inhibitor market is the growing demand for target therapies, the high prevalence of migraine and the unmet medical requirement of migraine care. During the forecast period, 2024-2029, Global CGRP Inhibitor is expected to expand at a CAGR of 21%. High-throughput screening, genomics, and bioinformatics technologies have enabled rapid identification and validation of potential drug targets, such as the CGRP pathway. These technologies expedited the discovery of CGRP as a key player in migraine pathophysiology. They facilitated the identification of the CGRP receptor as a potential therapeutic target for the development of CGRP inhibitors.

CGRP inhibitors have prompted a paradigm shift in migraine treatment, transitioning from predominantly acute symptom relief to preventive management. This shift aligns with the broader healthcare trend of focusing on proactive and preventive care to enhance patient well-being. By offering an option for preventing migraine attacks, CGRP inhibitors provide patients with a greater degree of control over their condition, reducing the need for reactive interventions and emergency care.

The Intravenous segment is gaining widespread acceptance owing to the quickest onset of action in the Intravenous route since the drug is directly delivered into the bloodstream. This could be beneficial for severe, acute migraine attacks. Additionally, some patients may have difficulty administering subcutaneous injections themselves or may prefer to have medical professionals administer the medication. In such cases, hospitals could play a role in providing intravenous CGRP inhibitors.

The development and commercialisation of CGRP inhibitors showcase pharmaceutical innovation at its finest. The discovery of CGRP's pivotal role in migraine pathophysiology and the subsequent design of targeted inhibitors highlights the industry's commitment to advancing patient care. This innovation extends beyond drug development to encompass novel drug delivery methods, formulations, and dosing regimens that enhance patient convenience and adherence.

Advancements in understanding the genetic and physiological underpinnings of migraine have paved the way for personalized medicine approaches. CGRP inhibitors exemplify this trend by enabling healthcare providers to tailor treatment plans based on individual patient profiles, preferences, and responsiveness. This personalized approach enhances treatment outcomes and patient satisfaction, driving demand for CGRP inhibitors.

Scope of the Report:

• The report analyses the CGRP Inhibitor Market by Value (USD Million).

• The report presents the analysis of CGRP Inhibitor Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.

• The report analyses the CGRP Inhibitor Market by Treatment (Preventive, Acute).

• The report analyses the CGRP Inhibitor Market by Route of Administration (Oral, Nasal, Intravenous).

• The report analyses the CGRP Inhibitor Market by End-User (Hospitals, Pharmacies, Specialty Clinics).

• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by services, by mode of operation & by end users.

• Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Eli Lilly and Company, Pfizer, Teva Pharmaceuticals, Lundbeck, AbbVie Inc., Amgen Inc. and Novartis.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

Azoth Analytics社の健康分野での最新刊レポート

本レポートと同じKEY WORD（inhibitor）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

CGRP阻害剤の世界市場（2023年版）：治療法別（予防、急性期）、投与経路別（経口、経鼻、静脈）、エンドユーザー別、地域別、国別の分析：市場インサイトと予測（2019-2029年）

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

Azoth Analytics社の健康分野での最新刊レポート

本レポートと同じKEY WORD（inhibitor）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?